Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
NCT ID: NCT05148000
Last Updated: 2024-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
25 participants
INTERVENTIONAL
2023-01-23
2023-06-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
NCT04247074
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NCT04225260
Treatment of Moderate to Severe Lateral Canthal Lines
NCT04249687
Treatment of Moderate to Severe Glabellar Lines
NCT04249583
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QM1114-DP
QM1114-DP
QM1114-DP
QM1114-DP
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QM1114-DP
QM1114-DP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe bilaterally symmetrical LCL as assessed by the investigator
* Moderate to severe GL at maximum frown as assessed by the Investigator
Exclusion Criteria
* Female who is pregnant, breast feeding or intends to conceive a child during the study.
* Known allergy to hypersensitivity or any component of the Investigational product
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma Research Site
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
43QM2107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.